labmt: impact of treatment prior to allogenic hct in mds
Published 4 years ago • 40 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
1:47
shared treatment decision-making
-
5:07
daratumumab in the management of al amyloidosis
-
50:38
hf across all spectrum of ef, an overview -cardiology - copm weekly24
-
39:55
session 6: tefca time
-
14:56
the extrinsic coagulation cascade
-
5:18
upfront treatment in transplant candidates
-
8:34
hct in mds: cell source and conditioning type
-
1:53
the future of multiple myeloma treatment
-
1:02
maintenance therapy following treatment for amyloidosis
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
3:28
molecular prognostication in smm
-
8:40
lenalidomide, mutations & mds outcomes
-
2:20
ultra high-risk myeloma
-
2:12
allre08 pethema: pediatric regimen for adolescents with ph-negative all
-
2:09
heart transplantation in attr amyloidosis
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
3:10
novel aml treament approaches
-
1:33
rnai therapeutics for attr amyloidosis
-
3:40
master class in transplantation and hematology: highlights